text: <unk>  is an colony stimulating factor that is FDA approved for the treatment of to reduce the duration of severe neutropenia in patients with non‑myeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a clinically significant incidence of febrile neutropenia.   Common adverse reactions include Splenic rupture , Acute Respiratory Distress Syndrome , Serious Allergic Reactions , Capillary leak syndrome.
option_0: Tbo-filgrastim
option_1: Filgrastim
option_2: Pegfilgrastim
option_3: Romiplostim
option_4: Interferon Alfa-n3
option_5: Tositumomab
option_6: Aldesleukin
option_7: Interferon alfa-2a